Islet Sciences reports results from two Phase IIb clinical studies for type 2 diabetics drug
The two Phase IIb clinical studies were double-blind, pioglitazone-controlled, dose-ranging studies designed to assess the safety, efficacy and tolerability of multiple remogliflozin etabonate doses for 12-weeks in treatment-naïve
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.